[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357264-105":59,"doc-detail-357264-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cuproptosis-as-a-novel-predictor-of-immunotherapy-response-and-shapes-the-immune-landscape-in-pan-cancer-analysis","Cuproptosis as a novel predictor of immunotherapy response and shapes the immune landscape in pan-cancer analysis","","Cancer heterogeneity makes immunotherapy response difficult to predict, motivating reliable biomarkers. Cuproptosis, a recently defined regulated cell death driven by copper-dependent proteotoxic stress in the mitochondria TCA cycle, has an unclear role in antitumor immunity. This study builds a cuproptosis score and links it to immunotherapy outcomes across 23 cancers using multi-omics analyses. Results integrate bulk/single-cell transcriptomics, spatial transcriptomics, and metabolomics to map extrinsic and intrinsic immune landscapes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cuproptosis-as-a-novel-predictor-of-immunotherapy-response-and-shapes-the-immune-landscape-in-pan-cancer-analysis/357264/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cuproptosis-as-a-novel-predictor-of-immunotherapy-response-and-shapes-the-immune-landscape-in-pan-cancer-analysis/357264.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is cuproptosis, and how is it linked to antitumor immunity in this study?","Question",{"text":113,"@type":114},"Cuproptosis is a regulated cell death type driven by copper-dependent proteotoxic stress in the mitochondrial TCA cycle. The study evaluates how this process contributes to antitumor immunity through immune landscape remodeling and patient outcome associations.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is the cuproptosis score used to evaluate immunotherapy response?",{"text":118,"@type":114},"A cuproptosis score is established to characterize the immune landscape across 23 human cancers. Multi-omics analysis then correlates the score with patient immunotherapy outcomes.",{"name":120,"@type":111,"acceptedAnswer":121},"What differences are observed between cuproptosis-low and cuproptosis-high patients or tumors?",{"text":122,"@type":114},"Cuproptosis-low patients show improved immunotherapy outcomes, with increased immune infiltration and function and higher expression of cytokines, checkpoints, and MHC molecules. Cuproptosis-low tumors also display enriched metabolic and signaling pathways associated with antitumor immunity and immunogenicity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},357264,1790469012,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398046744996,"Pan etal. Discover Oncology (2026) 17:920 [https://doi.org/10.1007/s12672-026-05070-5](https://doi.org/10.1007/s12672-026-05070-5)  \nDiscover Oncology  \nANALYSIS Open Access  \nCuproptosis as a novel predictor   \nof immunotherapy response and shapes the immune landscape in pan-cancer analysis  \nYitong Pan1,2, Xiaodi Hu2* and Jun Cheng2*  \n*Correspondence: Xiaodi Hu [huxiaodi@hnca.org.cn](huxiaodi@hnca.org.cn)[ ](huxiaodi@hnca.org.cn)Jun Cheng [chengjun@hnca.org.cn](chengjun@hnca.org.cn)  \n1Furong Laboratory, Central South University, Changsha 410078, Hunan, China  \n2Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, China  \nAbstract  \nThe heterogeneity of cancer renders its response to immunotherapy elusive, warranting the identification of robust biomarkers for evaluation. As a form of recently defined regulated cell death (RCD), cuproptosis is driven by copperdependent proteotoxic stress in mitochondria tricarboxylic acid cycle (TCA cycle), exerting a sophisticated role in antitumor immunity, yet remains poorly understood. Here, we established a cuproptosis score to characterize the immune landscape across 23 human cancers and established the correlation of cuproptosis score with patient immunotherapy outcomes through multi-omics analysis. Bulk and singlecell transcriptomic analysis revealed that with cuproptosis-low patients tend to have improved immunotherapy outcomes compared to those with high cuproptosis scores, with increased immune infiltration and function, as well as abundant cytokines, checkpoints and major histocompatibility complex (MHC) molecules expression. Spatial transcriptomic analysis indicated that immune cells exhibited higher cuproptosis scores than tumor cells, hinting that immune cells are vulnerable to cuproptosis. Further metabolomic and transcriptomic analysis of underlying intrinsic features revealed that cuproptosis-low tumors exhibited a metabolic and signaling pathway profile enrichment favoring antitumor immunity and potent immunogenicity. Overall, our multi-omics analysis suggests cuproptosis score as a robust biomarker for immunotherapy benefit in multiple cancers, reveals cuproptosisrelated extrinsic and intrinsic immune landscapes, and provides a broad framework for understanding the relevance of cuproptosis to cancer immunology and clinical benefits of immunotherapy.  \nKeywords Cuproptosis, Regulated cell death, Antitumor immunity, Multi-omics immune landscapes, Immunotherapy  \n1 Introduction  \nHitherto, the continuous advances in the immuno-oncology and the development of immunotherapeutic agents, such as checkpoint inhibitors (CPIs) and chimeric antigen receptor (CAR) T cell therapy, provide promising strategies to overcome tumors by activating endogenous immune system [1]. However, there remain many patients with  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nPan et al. Discover Oncology (2026) 17:920 Page 2 of 23  \nlimited or absent benefit from immunotherapy. Therefore, identifying the popula","cbCain9dHjphD0RB","https://ap.wps.com/l/cbCain9dHjphD0RB","pdf",6776535,23,"English","# Introduction\n# Cuproptosis score and immune landscape across cancers\n## Multi-omics analysis of immunotherapy outcomes\n## Transcriptomic and spatial immune cell patterns\n## Metabolomic and signaling pathway features","[{\"question\":\"What is cuproptosis, and how is it linked to antitumor immunity in this study?\",\"answer\":\"Cuproptosis is a regulated cell death type driven by copper-dependent proteotoxic stress in the mitochondrial TCA cycle. The study evaluates how this process contributes to antitumor immunity through immune landscape remodeling and patient outcome associations.\"},{\"question\":\"How is the cuproptosis score used to evaluate immunotherapy response?\",\"answer\":\"A cuproptosis score is established to characterize the immune landscape across 23 human cancers. Multi-omics analysis then correlates the score with patient immunotherapy outcomes.\"},{\"question\":\"What differences are observed between cuproptosis-low and cuproptosis-high patients or tumors?\",\"answer\":\"Cuproptosis-low patients show improved immunotherapy outcomes, with increased immune infiltration and function and higher expression of cytokines, checkpoints, and MHC molecules. Cuproptosis-low tumors also display enriched metabolic and signaling pathways associated with antitumor immunity and immunogenicity.\"}]","Cuproptosis as a novel predictor of immunotherapy response and shapes the immune landscape in pan-cancer analysis | PDF",1790129518,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fe0016f0625596d9d9de40296f83cd0.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/244493ca05894c168c853a43f3bd115b.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d454c074708ec06ba5bd6fe1ff63e6bf.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc3e93725d8a67d5482e4d3114fdc606.webp",980,1306]